Phosphoproteomic Profiling Reveals mTOR Signaling in Sustaining Macrophage Phagocytosis of Cancer Cells

被引：0
作者：
Wang, Bixin [1 ]
Cao, Xu [1 ]
Garcia-Mansfield, Krystine [2 ,3 ]
Zhou, Jingkai [1 ]
Manousopoulou, Antigoni [1 ]
Pirrotte, Patrick [2 ,3 ]
Wang, Yingyu [4 ]
Wang, Leo D. [1 ,5 ]
Feng, Mingye [1 ]
机构：
[1] City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunooncol, Duarte, CA 91010 USA
[2] Translat Genom Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA
[3] City Hope Comprehens Canc Ctr, Integrated Mass Spectrometry Shared Resource, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Ctr Informat, Duarte, CA 91010 USA
[5] CITY HOPE NATL MED CTR, DEPT PEDIAT, DUARTE, CA 91010 USA
来源：
CANCERS | 2024年 / 16卷 / 24期
关键词：
macrophage; mTOR; phosphoproteomics; cancer immunotherapy; MAMMALIAN TARGET; DENDRITIC CELLS; IN-VIVO; PHOSPHORYLATION; CD47; GENERATION; MATURATION; RECEPTORS;
D O I：
10.3390/cancers16244238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Macrophage-mediated cancer cell phagocytosis has demonstrated considerable therapeutic potential. While the initiation of phagocytosis, facilitated by interactions between cancer cell surface signals and macrophage receptors, has been characterized, the mechanisms underlying its sustentation and attenuation post-initiation remain poorly understood. Methods: Through comprehensive phosphoproteomic profiling, we interrogated the temporal evolution of the phosphorylation profiles within macrophages during cancer cell phagocytosis. Results: Our findings reveal that activation of the mTOR pathway occurs following the initiation of phagocytosis and is crucial in sustaining phagocytosis of cancer cells. mTOR inhibition impaired the phagocytic capacity, but not affinity, of the macrophages toward the cancer cells by delaying phagosome maturation and impeding the transition between non-phagocytic and phagocytic states of macrophages. Conclusions: Our findings delineate the intricate landscape of macrophage phagocytosis and highlight the pivotal role of the mTOR pathway in mediating this process, offering valuable mechanistic insights for therapeutic interventions.
引用
收藏
页数：20
相关论文
共 89 条
  • [1] Cassetta L., Pollard J.W., Targeting macrophages: Therapeutic approaches in cancer, Nat. Rev. Drug Discov, 17, pp. 887-904, (2018)
  • [2] Qian B.-Z., Pollard J.W., Macrophage Diversity Enhances Tumor Progression and Metastasis, Cell, 141, pp. 39-51, (2010)
  • [3] Kumar S., Mittal S., Gupta P., Singh M., Chaluvally-Raghavan P., Pradeep S., Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment, Cancers, 14, (2022)
  • [4] Atri C., Guerfali F.Z., Laouini D., Role of Human Macrophage Polarization in Inflammation during Infectious Diseases, Int. J. Mol. Sci, 19, (2018)
  • [5] Chen S., Lai S.W.T., Brown C.E., Feng M., Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy, Front. Immunol, 12, (2021)
  • [6] Feng M., Jiang W., Kim B.Y.S., Zhang C.C., Fu Y.-X., Weissman I.L., Phagocytosis checkpoints as new targets for cancer immunotherapy, Nat. Rev. Cancer, 19, pp. 568-586, (2019)
  • [7] Mantovani A., Allavena P., Marchesi F., Garlanda C., Macrophages as tools and targets in cancer therapy, Nat. Rev. Drug Discov, 21, pp. 799-820, (2022)
  • [8] Marquardt V., Theruvath J., Pauck D., Picard D., Qin N., Blumel L., Maue M., Bartl J., Ahmadov U., Langini M., Et al., Tacedinaline (Ci-994), a Class I Hdac Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in Myc-Driven Medulloblastoma While Making Them Susceptible to Anti-Cd47-Induced Macrophage Phagocytosis Via Nf-Kb-Tgm2 Driven Tumor Inflammation, J. Immunother. Cancer, 11, (2023)
  • [9] Gholamin S., Mitra S.S., Feroze A.H., Liu J., Kahn S.A., Zhang M., Esparza R., Richard C., Ramaswamy V., Remke M., Et al., Disrupting the Cd47-Sirpalpha Anti-Phagocytic Axis by a Humanized Anti-Cd47 Antibody Is an Efficacious Treatment for Malignant Pediatric Brain Tumors, Sci. Transl. Med, 9, (2017)
  • [10] Jutras I., Desjardins M., PHAGOCYTOSIS: At the Crossroads of Innate and Adaptive Immunity, Annu. Rev. Cell Dev. Biol, 21, pp. 511-527, (2005)
123456789